News | April 28, 2026
Essilor Stellest lens positioned as key breakthrough in myopia control in India
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
nSEPIA aims to bring structure to an area long dominated by subjectivity
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The deal signals a clear push to expand access to care in underserved regions
Subscribe To Our Newsletter & Stay Updated
